Five Prime Therapeutics presents data from FPA144 in urothelial cancer
Five Prime Therapeutics announced that a poster featuring data related to FPA144 in urothelial cancer, UC, also known as bladder cancer, was presented today at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany. The Poster titled "FGFR2b Represents a Novel Target for Treatment of Urothelial Cancer," is available at URL "This translational data suggest that FGFR2b protein is expressed in a subset of bladder cancers," said Robert Sikorski, M.D., Ph.D., senior vice president and chief medical officer of Five Prime. "In our Phase 1 clinical trial, a patient with bladder cancer that expressed FGFR2b achieved a complete response after treatment with FPA144. We are actively investigating FPA144 as a treatment for gastric cancer and are now exploring its clinical potential in bladder cancer."